Tyrosine kinase inhibitors in treating soft tissue sarcomas: Sunitinib in non-GIST sarcomas

Clinical and Translational Oncology

Volumn 12, Issue 7, 2010, Pages 468-472

  Homet Moreno, Blanca ^a   Garralda Cabanas, Elena ^a   Hitt, Ricardo ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Soft tissue sarcoma; Sunitinib malate; TK inhibitors

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ANTHRACYCLINE DERIVATIVE; CD135 ANTIGEN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IFOSFAMIDE; IMATINIB; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; RNA BINDING PROTEIN EWS; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHORDOMA; CLEAR CELL SARCOMA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DERMATOFIBROSARCOMA PROTUBERANS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; EWING SARCOMA; FATIGUE; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG EMBOLISM; MALIGNANT FIBROUS HISTIOCYTOMA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; RHABDOMYOSARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SURVIVAL TIME; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; THROMBOSIS; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; SARCOMA;

EID: 77956014125     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0539-z     Document Type: Review

References (41)

1. M. Van Glabbeke A.T. van Oosterom J.W. Oosterhuis, et al. 1999 Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study J Clin Oncol 17 150 157 10458228
2. J.C. Yang A.E. Chang A.R. Baker, et al. 1982 Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity J Clin Oncol 16 197 203
3. S. Rosenberg J. Tepper E. Glatstein, et al. 1982 The treatment of soft-tissue sarcoma of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy Ann Surg 196 305 315 10.1097/00000658- 198209000-00009 1:STN:280:DyaL383ot12nsg%3D%3D 7114936
4. L.B. Harrison F. Franzese J.J. Gaynor, et al. 1993 Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk Int J Radiat Oncol Biol Phys 27 259 265 1:STN:280:DyaK2c%2Fht1Siuw%3D%3D 8407399
5. T.F. DeLaney I.J. Spiro H.D. Suit, et al. 2003 Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas Int J Radiat Oncol Biol Phys 564 1117 1127 10.1016/S0360-3016(03)00186-X
6. M. Van Glabbeke A.T. van Oosterom J.W. Oosterhuis, et al. 1999 Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: an analysis of 2,185 patients treated with anthracycline containing first-line regimens-an European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Study Group J Clin Oncol 17 150 157 10458228
7. P.C. Lorigan J. Verweij Z. Papai, et al. 2002 Randomised phase III trial of two investigational schedules of ifosfamide versus standard dose doxorubicin in patients with advanced or metastatic soft tissue sarcoma (ASTS) Proc Am Soc Clin Oncol 21 1616
8. L.J. Helman P. Meltzer 2003 Mechanisms of sarcoma development Nat Rev Cancer 3 685 694 10.1038/nrc1168 1:CAS:528:DC%2BD3sXmvVWlu7k%3D 12951587
9. G.L. Nichols 2003 Tyrosine kinase inhibitors as cancer therapy Cancer Invest 21 758 771 10.1081/CNV-120023774 1:CAS:528:DC%2BD3sXnvFWgt7w%3D 14628434
10. S. Hirota K. Isozaki Y. Moriyama, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D 9438854
11. M. Debiec-Rychter R. Sciott A. LeCesne, et al. 2006 KIT mutations and dose selection for imatinib in patients with advances gastrointestinal stromal tumours Eur J Cancer 42 1093 1103 10.1016/j.ejca.2006.01.030 1:CAS:528:DC%2BD28Xks1ertb0%3D 16624552
12. S.C. Linn R.B. West J.R. Pollack, et al. 2003 Gene expression pattern and gene copy number changes in dermatofibrosarcoma protuberans Am J Pathol 163 2383 2395 1:CAS:528:DC%2BD2cXkslKn 14633610
13. H.B. Koon G.J. Bubley L. Pantanowitz, et al. 2005 Imatinib-induced regression of AIDS-related Kaposi's sarcoma J Clin Oncol 23 982 989 10.1200/JCO.2005.06.079 1:CAS:528:DC%2BD2MXit1Gnsr8%3D 15572730
14. N.C. Daw W.L. Furman C.F. Stewart, et al. 2005 Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 23 6172 6180 10.1200/JCO.2005.11. 429 1:CAS:528:DC%2BD2MXhtVKgtbrN 16135484
15. K. Scotlandi M.C. Manara C.M. Hattinger, et al. 2005 Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma Eur J Cancer 41 1349 1361 10.1016/j.ejca.2005.03.015 1:CAS:528:DC%2BD2MXltFCkt7o%3D 15913990
16. A.A. Azizi C. Haberler T. Czech, et al. 2006 Vascular-endothelial-growth factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma Lancet Oncol 7 521 523 10.1016/S1470-2045(06)70729-X 16750504
17. J. Ahlén J. Wejde O. Brosjö, et al. 2005 Insulinlike growth factor type 1 receptor expression correlates to good prognosis in highly malignant soft tissue sarcoma Clin Cancer Res 11 206 216 15671548
18. A.C. Shor E.A. Keschman F.Y. Lee, et al. 2007 Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on Src kinase for survival Cancer Res 67 2800 2808 10.1158/0008-5472.CAN-06-3469 1:CAS:528:DC%2BD2sXivV2nsb4%3D 17363602
19. B. Gusterson G. Cowley J. McIlhinney, et al. 1985 Evidence for increased epidermal growth factor receptors in human sarcomas Int J Cancer 36 689 693 10.1002/ijc.2910360612 1:CAS:528:DyaL28Xms1Oqtw%3D%3D 2999006
20. V. Wallenius M. Hisaoka K. Helou, et al. 2000 Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors Am J Pathol 156 821 829 1:CAS:528: DC%2BD3cXitVerurk%3D 10702398
21. T. Motoi T. Ishida M. Kuroda, et al. 1998 Coexpression of hepatocyte growth factor and c-Met proto-oncogene product in synovial sarcoma Pathol Int 48 769 775 10.1111/j.1440-1827.1998.tb03836.x 1:CAS:528:DyaK1cXmvFKhsLg%3D 9788260
22. Chow LQM, Eckhardt SG (2007) Sunitinib: From rational design to clinical efficacy. J Clin Oncol 884-896
23. R.J. Motzer T.E. Hutson P. Tomczak, et al. 2007 Sunitinib versus interferon alfa in metastatic renal cell carcinoma N Engl J Med 356 115 124 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D 17215529
24. G.D. Demetri A.T. van Oosterom C.R. Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: A randomized controlled trial Lancet 368 1329 1338 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL 17046465
25. A. Gazit H. Igarashi I.M. Chiu, et al. 1984 Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation Cell 39 89 97 10.1016/0092-8674(84)90194-6 1:CAS:528:DyaL2MXhvVOruw%3D%3D 6091919
26. C.L. Corless A. Schroeder D. Griffith, et al. 2005 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib J Clin Oncol 23 5357 5364 10.1200/JCO.2005.14.068 1:CAS:528: DC%2BD2MXpslOrtLY%3D 15928335
27. U. McDermott R.Y. Ames A.J. Iafrate, et al. 2009 Ligand-dependent platelet-derived growth factor receptor (PDGFR)-A activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors Cancer Res 69 3937 3946 10.1158/0008-5472.CAN-08-4327 1:CAS:528:DC%2BD1MXltFOksbw%3D 19366796
28. S. George P. Merriam R.G. Maki, et al. 2009 Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas J Clin Oncol 27 3154 3160 10.1200/JCO.2008.20.9890 1:CAS:528:DC%2BD1MXhtFWitb3E 19451429
29. E.A. Eisenhauer 2007 Response evaluation: beyond RECIST Ann Oncol 18 [Suppl9] ix29 32 10.1093/annonc/mdm290 17631592
30. G.A. McArthur G.D. Demetri A. van Oosterom, et al. 2005 Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium Study B2225 J Clin Oncol 23 866 873 10.1200/JCO.2005.07.088 1:CAS:528:DC%2BD2MXitVKit7g%3D 15681532
31. M.C. Heinrich G.A. McArthur G.D. Demetri, et al. 2006 Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoids tumor) J Clin Oncol 24 1195 1203 10.1200/JCO.2005.04.0717 1:CAS:528:DC%2BD28XislGgtr8%3D 16505440
32. P.G. Casali A. Messina S. Stacchiotti, et al. 2004 Imatinib mesylate in chordoma Cancer 101 2086 2097 10.1002/cncr.20618 1:CAS:528:DC%2BD2cXhtVShtb7J 15372471
33. E. Tamborini F. Miselli T. Negri, et al. 2006 Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA and KIT receptors in chordomas Clin Cancer Res 12 6920 6928 10.1158/1078-0432.CCR-06- 1584 1:CAS:528:DC%2BD28Xht1Kns7vO 17145809
34. D. Tuveson J.A. Fletcher 2001 Signal transduction pathways in sarcoma as targets for therapeutic intervention Curr Opin Oncol 13 249 255 10.1097/00001622-200107000-00007 1:CAS:528:DC%2BD3MXlt1Ogs7o%3D 11429482
35. Vigil CE, Chiaporri AA, Williams CA et al (2008) Phase II of sunitinib malate (SM) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II study. J Clin Oncol 26[Suppl]: (Abstr. 10535)
36. M.L. Hensley M.W. Sill D.R. Scribner Jr, et al. 2009 Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study Gynecol Onco 115 460 465 10.1016/j.ygyno.2009.09. 011 1:CAS:528:DC%2BD1MXhtlCnurvM
37. 18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) J Clin Oncol 20 Suppl 362a
38. S. Stroobants J. Goeminne M. Seegers, et al. 2003 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec) Eur J Cancer 39 2012 2020 10.1016/S0959-8049(03)00073-X 1:CAS:528:DC%2BD3sXmvVKgt74%3D 12957455
39. H. Choi 2005 Critical issues in response evaluation on computed tomography: Lessons from the gastrointestinal stromal tumor model Curr Oncol Rep 7 307 311 10.1007/s11912-005-0055-4 15946591
40. C.H. Holdsworth R.D. Badawi J. Manola, et al. 2007 CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor AJR Am J Roentgenol 189 324 330 10.2214/AJR.07.2496
41. M. Van Glabbeke J. Verweij I. Judson, et al. 2002 Progression-free rate as the principal end-point for phase II trials in soft tissue sarcoma Eur J Cancer 38 543 549 10.1016/S0959-8049(01)00398-7 11872347